Drugs and Devices

February 2017 Vol. 12 No. 2

On Feb. 9, the U.S. Food and Drug Administration (FDA) approved Emflaza (deflazacort) tablets and oral suspension to treat patients age 5 years and older with Duchenne muscular dystrophy (the most common type of muscular dystrophy). Read more . . .

February 2017 Vol. 12 No. 2

On Feb. 15, the U.S. Food and Drug Administration (FDA) approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Read more . . .

January 2017 Vol. 12 No. 1

On Jan. 27, the U.S. Food and Drug Administration (FDA) warned that homeopathic teething tablets containing belladonna pose an unnecessary risk to infants and children and urges consumers not to use these products. Read more . . .

January 2017 Vol. 12 No. 1

On Jan. 29, the U.S. Food and Drug Administration (FDA) approved Trulance (plecanatide) for the treatment of chronic idiopathic constipation. Read more . . .

January 2017 Vol. 12 No. 1

The Annals of Internal Medicine has published a new guideline on the pharmacologic treatment of hypertension in adults 60 years or older and target blood pressure goals. Read more . . .

January 2017 Vol. 12 No. 1

An article in The Gerontologist discusses the implications of the rising use of cannabis in older Americans. Read more . . .

December 2016 Vol. 11 No. 12

On Dec. 20, the Food and Drug Administration (FDA) expanded the approved use of Dexcom’s G5 Mobile Continuous Glucose Monitoring System to allow for replacement of fingerstick blood glucose testing for diabetes treatment decisions in people 2 years of age and older with diabetes. Read more . . .

December 2016 Vol. 11 No. 12

On Dec. 19, the Food and Drug Administration (FDA) approved Rubraca (rucaparib) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have the gene mutation deleterious BRCA as identified by an FDA-approved companion diagnostic test. Read more . . .

December 2016 Vol. 11 No. 12

On Dec. 14, the Food and Drug Administration (FDA) approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema in patients 2 years of age and older. Read more . . .